Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9333169rdf:typepubmed:Citationlld:pubmed
pubmed-article:9333169lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:9333169lifeskim:mentionsumls-concept:C0039195lld:lifeskim
pubmed-article:9333169lifeskim:mentionsumls-concept:C0149678lld:lifeskim
pubmed-article:9333169lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:9333169lifeskim:mentionsumls-concept:C0040627lld:lifeskim
pubmed-article:9333169lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:9333169lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:9333169lifeskim:mentionsumls-concept:C0205322lld:lifeskim
pubmed-article:9333169lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:9333169lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:9333169lifeskim:mentionsumls-concept:C1527180lld:lifeskim
pubmed-article:9333169pubmed:issue4lld:pubmed
pubmed-article:9333169pubmed:dateCreated1997-11-6lld:pubmed
pubmed-article:9333169pubmed:abstractTextFive healthy human leukocyte antigen-B8 (HLA-B8)-positive virus carriers were studied to investigate the CD8+ cytotoxic T lymphocyte (CTL) response to an HLA-B8-restricted peptide, RAKFKQLLQ, located in the Epstein-Barr virus (EBV) immediate-early trans-activator protein, BZLF1. Of the 5 virus carriers, 4 were infected with type A and 1 with type B EBV. Using limiting-dilution analysis of peripheral blood mononuclear cells, a high RAKFKQLLQ-specific CTL precursor frequency was demonstrated after specific peptide or autologous lymphoblastoid cell line stimulation in both type A and type B EBV carriers. The RAKFKQLLQ-specific CTL precursor frequencies in all 5 persons were at least as dominant as those observed with two other EBV-associated, HLA-B8-restricted latent epitopes, FLRGRAYGL and QAKWRLQTL. These findings show that healthy virus carriers maintain a high frequency of BZLF1-specific memory T cells, potentially to control virus spread from lytically infected cells.lld:pubmed
pubmed-article:9333169pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9333169pubmed:languageenglld:pubmed
pubmed-article:9333169pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9333169pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9333169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9333169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9333169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9333169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9333169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9333169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9333169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9333169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9333169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9333169pubmed:statusMEDLINElld:pubmed
pubmed-article:9333169pubmed:monthOctlld:pubmed
pubmed-article:9333169pubmed:issn0022-1899lld:pubmed
pubmed-article:9333169pubmed:authorpubmed-author:MiskoI SISlld:pubmed
pubmed-article:9333169pubmed:authorpubmed-author:SchmidtCClld:pubmed
pubmed-article:9333169pubmed:authorpubmed-author:SilinsS LSLlld:pubmed
pubmed-article:9333169pubmed:authorpubmed-author:ElliottS LSLlld:pubmed
pubmed-article:9333169pubmed:authorpubmed-author:CrossS MSMlld:pubmed
pubmed-article:9333169pubmed:authorpubmed-author:PyeS JSJlld:pubmed
pubmed-article:9333169pubmed:issnTypePrintlld:pubmed
pubmed-article:9333169pubmed:volume176lld:pubmed
pubmed-article:9333169pubmed:ownerNLMlld:pubmed
pubmed-article:9333169pubmed:authorsCompleteYlld:pubmed
pubmed-article:9333169pubmed:pagination1068-72lld:pubmed
pubmed-article:9333169pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:meshHeadingpubmed-meshheading:9333169-...lld:pubmed
pubmed-article:9333169pubmed:year1997lld:pubmed
pubmed-article:9333169pubmed:articleTitleDominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection.lld:pubmed
pubmed-article:9333169pubmed:affiliationEpstein Barr Virus Unit, Queensland Institute of Medical Research, Brisbane, Australia.lld:pubmed
pubmed-article:9333169pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9333169pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9333169pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9333169lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9333169lld:pubmed